Apotex, the largest Canadian-based pharmaceutical company, announced that Health Canada has granted a Notice of Compliance (NOC) for LOQTORZI for the treatment of nasopharyngeal carcinoma (NPC), an ultra-rare and aggressive cancer. 

This approval marks a significant milestone. LOQTORZI is the first and only Health Canada-approved immuno-therapy for patients with recurrent unresectable or metastatic nasopharyngeal cancer (R/M NPC), offering an effective new immuno-therapy option to patients facing this challenging malignancy.

Health Technology Insights: ExaCare AI Raises $30 Million to Transform Nursing Admissions

LOQTORZI is indicated:

  • In combination with cisplatin and gemcitabine for adults with metastatic or recurrent locally advanced NPC.
  • As a monotherapy for adults with recurrent unresectable or metastatic NPC who have progressed following platinum-based chemotherapy.

This approval introduces Apotex’s first novel biologic therapy – a targeted immuno-therapy, underscoring the company’s commitment to expanding access to innovative oncology treatments in Canada. It represents a strategic evolution of Apotex’s portfolio, which includes providing options for patients with rare and hard-to-treat cancers. Apotex secured the Canadian rights to LOQTORZI through an agreement with Coherus BioSciences.

Health Technology Insights: Microsoft Expands Dragon Copilot AI for Nurses and Partners

“LOQTORZI exemplifies our commitment to Canadian patients and the healthcare system,” said Allan Oberman, President & CEO, Apotex. “As the first and only Health Canada-approved immuno-therapy for both the first and later-line treatment of this unique cancer, it delivers a transformative therapy where none previously existed, addressing a critical unmet need.”

“The availability of LOQTORZI in Canada is a meaningful step forward for patients diagnosed with nasopharyngeal carcinoma,” said Dr. Nathaniel Bouganim, Medical Oncologist and Division Director of Medical Oncology, McGill University Health Centre. “Having this therapy accessible through a Canadian-based pharmaceutical company like Apotex helps promote equitable care for those facing this rare disease.

As a Force for Health, Apotex continues to build on its strategic vision, expanding its presence in pharmaceutical and consumer health products while maintaining its core focus on improving everyday access to critical medicines for patients.

Health Technology Insights: INITIO Medical Named First ICPO Theranostics Center in North America

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source- PR Newswire